Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06151652
Other study ID # ALA post cardiac surgery
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 1, 2023
Est. completion date April 1, 2024

Study information

Verified date September 2023
Source Ain Shams University
Contact noha tarek mohammed, MSC
Phone 00201007541786
Email noha.tarek20@pharma.asu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ALA is administered orally since it is without difficulty absorbed in the stomach. ALA goes through the blood brain barrier and does not show toxic effects and actions at doses used for prophylactic and therapeutic purposes. This has encouraged us to use an efficient anti-oxidant and anti-inflammatory agent, alpha-lipoic acid (biochemical) as a relevant option to prevent POAF.


Description:

Investigators computed on the basis of findings from a prior study found the incidence of POAF after cardiac surgery of about 25% . Assuming a slightly lower alpha-lipoic acid' effect to previous study. If the true relative risk of AF for experimental subjects relative to controls is 0.5 , with α equivalent to 0.5 and power (1 - β) is 0.8, the estimated sample size is 152 experimental subjects and 152 control subjects in order to be able to reject the null hypothesis that this relative risk equals 1 with probability (power) of 0.8. investigators used the uncorrected chi-squared statistics to evaluate this null hypothesis. STATA software version and taking into account a possible dropout of 15%, the total sample size was: 304 + 0.15 (304) × 2 = 350 subjects of which there will be 175 controls and 175 experimental subjects %, assuming an enrolment ratio of 1:1.


Recruitment information / eligibility

Status Recruiting
Enrollment 350
Est. completion date April 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - I - Male or female patients above 18 years of age who are scheduled for cardiac surgery. Exclusion Criteria: - Any urgent or emergency surgery. - Poor Left ejection volume (EF < 30%). - Intake of steroids or any antiarrhythmic drugs except beta blockers during the last month before surgery - Unable or unwilling to provide informed written consent. - Pregnancy or lactation - Known hypersensitivity to the study drug. - Current treatment with antioxidants or alpha-lipoic acid for any indication. - Infection or inflammatory disease except coronary artery disease. - Left atrium size >70 mm.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Alpha Lipoic Acid 600 MG Oral Tablet
Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
Placebo
placebo

Locations

Country Name City State
Egypt Ain shams university Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary • Number of Participants with POAF 1 month
Secondary Total intensive care unit length-of-stay number of days at intensive care unit 3 months
Secondary Total hospital length-of-stay number of days at hospital 3 months
Secondary 30 days mortality deaths number 1-month
Secondary Serum creatinine creatinine level 5 days
Secondary Major adverse cardiovascular outcomes (Myocardial injury - Stroke - Permanent pacemaker - Pericardial effusion and pleural effusion- Bleeding) 1 month
Secondary Duration of ventilation hours needed to remove ventilator 5 days
See also
  Status Clinical Trial Phase
Recruiting NCT03857711 - Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation) N/A
Completed NCT02132767 - Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation Phase 3
Recruiting NCT03868150 - Prevention of Postop Atrial Fibrillation Through Intraoperative Inducibility of Atrial Fibrillation and Amiodarone Treatment Phase 4
Completed NCT01742039 - Prevention of Postoperative Atrial Fibrillation
Recruiting NCT05076019 - Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement N/A
Completed NCT03646773 - Microvascular Effects of Intravenous Esmolol During Postoperative Atrial Fibrillation
Completed NCT00765089 - Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation Phase 4
Recruiting NCT05730413 - Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery Phase 4
Completed NCT04307225 - Atrial Fibrillation After CABG and PCI
Completed NCT05009914 - A New Way of Cardiac Denervation to Reduce the Incidence of AF After CABG. N/A
Recruiting NCT03905759 - Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG Phase 2/Phase 3
Recruiting NCT06054360 - Predictive Value of Right Atrial Strain in Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Recruiting NCT05320705 - The Effect of Intra Operative Dexmedetomidine in Prevention of Early Postoperative Atrial Fibrillation Phase 1
Recruiting NCT05062239 - Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins N/A